Ethionamide

Summary

Ethionamide (CHEMBL1441) is an approved small-molecule antitubercular agent (ATC J04AD03); indicated across 4 conditions including tuberculosis and multidrug-resistant tuberculosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J04AD03
• Indications: 4 conditions
• Clinical trials: 5
• Chemistry: 166.25 Da · C8H10N2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1441
Name	Ethionamide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2761171
ChEBI	CHEBI:4885
ATC	J04AD03
Molecular formula	C8H10N2S
Molecular weight	166.25
InChIKey	AEOCXXJPGCBFJA-UHFFFAOYSA-N

SMILES: CCC1=NC=CC(=C1)C(=S)N

IUPAC name: 2-ethylpyridine-4-carbothioamide

ChEBI definition: A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.

Pharmacological roles (ChEBI): antitubercular agent, antilipemic drug, fatty acid synthesis inhibitor, leprostatic drug, prodrug.

Also known as: 1314 TH, BAYER 5312, Ethionamide, Ethionamidum, Etionamida, Nizotin, NSC-255115, Trecator, Trecator-sc, ethionamide, SID11112402, SID11532957

Patent coverage: 11,790 distinct patent families (38,311 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 38,266 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: DNA polymerase beta, Tyrosinase, Cytochrome P450 1A2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
O42713	5.4	IC50	4000	nM	CHEMBL_ACT_16406261

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
tuberculosis	4	MONDO:0018076	MONDO:0018076
multidrug-resistant tuberculosis	2	MONDO:0005861	EFO:0007381
pulmonary tuberculosis	2	MONDO:0006052	EFO:1000049
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
Not specified	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02454205	PHASE2/PHASE3	COMPLETED	An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
NCT05807399	PHASE2	RECRUITING	PanACEA - STEP2C -01
NCT05473195	PHASE2	COMPLETED	A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098
NCT00000796	Not specified	COMPLETED	A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
NCT00042289	Not specified	COMPLETED	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).